Baxter International Inc., a world pioneer in the manufacture and supply of sterile medicines, revealed that Baxter BioPharma Solutions has entered into an arrangement to provide sterile manufacturing services for NVX-CoV2373, the Novavax COVID-19 recombinant nanoparticle vaccine candidate with Matrix- M™adjuvant. Baxter BioPharma Solutions is a leading contract manufacturing company specialized in vaccines, including parenteral (injectable) medicines.
Agreement set to help increase production and promote access to the COVID-19 vaccines in the UK and European markets
Although the Novavax’ COVID-19 vaccine candidate is in Phase 3 study and has not yet been authorized for use by the regulatory authorities, the deal is expected to increase the manufacturing and distribution capacity of the COVID-19 vaccine on a commercial scale necessary for the United Kingdom’s and European markets.
Marie Keeley, Vice President, Baxter BioPharma Solutions stated:
“The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all. We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market.”
Novavax COVID-19 vaccine stable at standard storage temperatures of 2° C to 8° C
According to Novavax, the NVX-CoV2373 vaccine candidate includes a full-length, prefusion spike protein developed using the recombinant nanoparticle technology of Novavax and the company’s patented saponin-based Matrix-M™ adjuvant. The purified protein is encoded by the SARS-CoV-2 spike (S) protein genetic sequence and is produced in insect cells. It can neither induce nor replicate COVID-19 disease, is stable at 2° C to 8° C and is packaged in a liquid ready-to-use form that enables distribution using normal supply chain vaccine logistics.
Rick Crowley, Executive Vice President, Chief Operations Officer, Novavax, said:
“Our priority is to bring a safe, effective COVID-19 vaccine to people around the world. Partners like Baxter BioPharma Solutions are enabling Novavax to quickly establish a commercial supply chain network to ensure access for global populations, and ultimately help bring about an end to the global COVID-19 pandemic.”
Production of NVX-CoV2373 to take place at Baxter’s state-of-the-art Halle/Westfalen plant in Germany
Baxter’s NVX-CoV2373 production services will be performed at its state-of-the-art plant in Halle/Westphalia, Germany. The site has broad sterile manufacturing infrastructure and focus areas, currently offers good manufacturing practices (cGMP) with dedicated production sectors and is designed to deliver products to the market with high efficiency and speed. The manufacturing facility which has been in operation for more than 60 years was recently expanded. Further details of the agreement have not been disclosed.
About Baxter’s BioPharma Solutions Business
Through delivering scientific insights, sterile processing technologies, parenteral distribution systems and tailored support services needed to address the particular challenges that parenteral medicines face, Baxter’s BioPharma Solutions company assists leading pharmaceutical companies in achieving their commercialization targets.
For more information, please visit www.baxterbiopharmasolutions.com.
Millions of patients and healthcare providers depend on the leading portfolio of critical care, nutrition, renal, hospital, and surgical products from Baxter on a daily basis. Baxter has operated for more than 85 years in the critical field where the healthcare professionals who make it happen meet innovations that save and sustain lives.
Baxter’s workers globally are now drawing on the company’s rich legacy in medical breakthroughs with drugs, inventions and treatments available in more than 100 countries to advance the next wave of groundbreaking healthcare developments. To learn more, visit www.baxter.com